Ipsen reveals financial outcomes for 2009

Ipsen has unveiled its financial results for 2009, revealing a 7.6 per cent growth in drug sales for the period.

Consolidated group sales amounted to 1,032.8 million euros (900,000 pounds) for the whole of 2009 – a year-on-year increase of 6.8 per cent.

Sales generated in the major Western European countries during the year reached 554.7 million euros.

Its specialty care sales also increased in the fourth quarter by 16.1 per cent compared to the same period of 2008.

The firm stated that increases were driven by its dynamic specialty care franchises in the UK, Italy and Germany, but were offset by a tougher competitive environment in primary care in France.

Jean-Luc Belingard, chairman and chief executive officer of Ipsen, said: “Despite increasing pressure in the global healthcare environment, the group has once again demonstrated its ability to deliver on its objectives and sustain an above industry growth.”

In January, Ipsen signed a contract with Inspiration Biopharmaceuticals which will see them collaborate to create a leading haemophilia franchise.